QUÉBEC CITY, April 1, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,TSX: AEZ) (the "Company") today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.
|Abstract #3711:||"Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M. Teifel.|
|Presenter:||Irene Seipelt, PhD, Director, Preclinical Development at Aeterna Zentaris|
|Poster Session:||Experimental and Molecular Therapeutics 26|
|Date & Time:||Tuesday, April 8, 2014, 8 am-12 pm (Pacific time)|
|Venue:||Hall A-E, poster section 31, San Diego Convention Center|
AEZS-134 is an integral part of the Company's kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition. AEZS-134 selectively inhibits the kinase activity of Erk. AEZS-134 was discovered using the Company's proprietary compound library and high throughput screening technology. AEZS-134 is available for partnering.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development. For more information, visit www.aezsinc.com.
SOURCE: Aeterna Zentaris Inc.
For further information:
Director of Communications
(418) 652-8525 ext. 406